Human metapneumovirus (HMPV) is a major pediatric respiratory pathogen with 23 currently no specific treatment or licensed vaccine. Different strategies to prevent this infection have 24 been evaluated, including live-attenuated vaccines (LAV) based on SH and/or G protein deletions.
25This approach showed promising outcomes but has not been evaluated further using different viral 26 strains. In that regard, we previously showed that different HMPV strains harbor distinct in vitro 27 fusogenic and in vivo pathogenic phenotypes, possibly influencing the selection of vaccine strains.
28In this study, we investigated the putative contribution of the low conserved SH or G accessory 29 proteins in such strain-dependent phenotypes and generated recombinant wild type (WT) and SH-30 or G-deleted viruses derived from two different patient-derived HMPV strains, A1/C-85473 and 31 B2/CAN98-75.
32The ΔSH and ΔG deletions led to different strain-specific phenotypes in both LLC-MK2 cell and 33 reconstituted human airway epithelium models. More interestingly, the ΔG-85473 and especially 34 ΔSH-C-85473 recombinant viruses conferred significant protection against HMPV challenge and 35 induced immunogenicity against a heterologous strain. In conclusion, our results show that the viral 36 genetic backbone should be considered in the design of live-attenuated HMPV vaccines, and that a 37 SH-deleted virus based on the A1/C-85473 HMPV strain could be a promising LAV candidate as it 38 is both attenuated and protective in mice while being efficiently produced in a cell-based system.
40Keywords: human metapneumovirus (HMPV), live-attenuated vaccine (LAV), G protein, SH 41 protein, gene deletion, reverse genetics 42 43 44